Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 67ga Radioisotope
2. Ga-67 Radioisotope
3. Gallium-67
1. Gallium Citrate Ga 67
2. Gallium-67 Citrate
3. Gallium (67 Ga) Citrate
4. 41183-64-6
5. Gallium (67ga) Citrate
6. Gallium-(sup 67)ga Citrate (1:1)
7. Neoscan
8. Gallium ((sup 67)ga) Citrate
9. Gallium (67ga) Citrate [inn]
10. 4ljk511z86
11. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Gallium-(sup 67)ga (1:1) Salt
12. Gallium (67ga) Citrate (inn)
13. (67-ga)gallium Citrate
14. Gallium Citrate (ga67)
15. Einecs 255-248-4
16. Gallii (67 Ga) Citras
17. Gallii (67 Ga) Citras [inn-latin]
18. Citrato De Galio (67 Ga)
19. Citrate De Gallium (67 Ga)
20. Unii-4ljk511z86
21. Citrato De Galio (67 Ga) [inn-spanish]
22. Citrate De Gallium (67 Ga) [inn-french]
23. Gallium Citrate, Ga-67
24. 67ga Radioisotope
25. Neoscan (tn)
26. Ga-67 Radioisotope
27. Gallium 67 Citrate
28. Gallium Citrate,ga-67
29. Gallium Ga-67 Citrate
30. Gallium Citrate Ga 67 [usan:usp:jan]
31. Gallium Citrate (67 Ga)
32. Schembl9754280
33. Gallium Citrate Ga 67 (usp)
34. Gallium-67ga Citrate (1:1)
35. Gallium-67(3+); 2-hydroxypropane-1,2,3-tricarboxylate
36. Chebi:31645
37. Dtxsid70194107
38. Gallium Citrate Ga 67 [mi]
39. Db06784
40. Gallium Citrate Ga 67 [usan]
41. Gallium Citrate,ga-67 [vandf]
42. Gallium (67ga) Citrate [who-dd]
43. Gallium (67ga) Citrate Injection (jp17)
44. Gallium Citrate Ga-67 [orange Book]
45. Gallium Citrate Ga 67 [usp Impurity]
46. D01936
47. Q27260007
48. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Gallium-67ga (1:1) Salt
Molecular Weight | 256.03 g/mol |
---|---|
Molecular Formula | C6H5GaO7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 2 |
Exact Mass | 255.93173 g/mol |
Monoisotopic Mass | 255.93173 g/mol |
Topological Polar Surface Area | 141 Ų |
Heavy Atom Count | 14 |
Formal Charge | 0 |
Complexity | 211 |
Isotope Atom Count | 1 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions.
It has been reported in the scientific literature that following intravenous injection, the highest tissue concentration of gallium Ga-67 - other than tumors and sites of infection - is the renal cortex. After the first day, the maximum concentration shifts to bone and lymph nodes and after the first week, to liver and spleen. Gallium Ga-67 is excreted relatively slowly from the body. The average whole body retention is 65 percent after seven days, with 26 percent having been excreted in the urine and 9 percent in the stools.
V - Various
V09 - Diagnostic radiopharmaceuticals
V09H - Inflammation and infection detection
V09HX - Other diagnostic radiopharmaceuticals for inflammation and infection detection
V09HX01 - Gallium (67Ga) citrate
Absorption
The body generally handles Ga3+ as though it were ferric iron (Fe-III). However, gallium can not be reduced in vivo. Therefore, ferric ion is easily reduced and interacts with protoporphyrin IX to form heme, gallium remains bound to iron-transport proteins and carrier molecules.
Route of Elimination
No urinary excretion; elimination primarily via fecal excretion.
78.26 hours
Gallium Citrate Ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. The body generally handles Ga3+ as though it were ferric iron (Fe-III), and thus the free isotope ion is bound (and concentrates) in areas of inflammation, such as an infection site, and also areas of rapid cell division. Ga-67 binds to transferrin, leukocyte lactoferrin, bacterial siderophores, inflammatory proteins, and cell-membranes in neutrophils, both living and dead. Lactoferrin is contained within leukocytes. Ga-67 may bind to lactoferrin and be transported to sites of inflammation, or binds to lactoferrin released during bacterial phagocytosis at infection sites (and remains due to binding with macrophage receptors). Ga-67 also attaches to the siderophore molecules of bacteria themselves, and for this reason can be used in leukopenic patients with bacterial infection (here it attaches directly to bacterial proteins, and leukocytes are not needed). Uptake is thought to be associated with a range of tumour properties including transferring receptors, anaerobic tumor metabolism and tumor perfusion and vascular permeability.
Related Excipient Companies
Excipients by Applications
ABOUT THIS PAGE
A Gallium Citrate GA-67 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gallium Citrate GA-67, including repackagers and relabelers. The FDA regulates Gallium Citrate GA-67 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gallium Citrate GA-67 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gallium Citrate GA-67 supplier is an individual or a company that provides Gallium Citrate GA-67 active pharmaceutical ingredient (API) or Gallium Citrate GA-67 finished formulations upon request. The Gallium Citrate GA-67 suppliers may include Gallium Citrate GA-67 API manufacturers, exporters, distributors and traders.
click here to find a list of Gallium Citrate GA-67 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Gallium Citrate GA-67 DMF (Drug Master File) is a document detailing the whole manufacturing process of Gallium Citrate GA-67 active pharmaceutical ingredient (API) in detail. Different forms of Gallium Citrate GA-67 DMFs exist exist since differing nations have different regulations, such as Gallium Citrate GA-67 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Gallium Citrate GA-67 DMF submitted to regulatory agencies in the US is known as a USDMF. Gallium Citrate GA-67 USDMF includes data on Gallium Citrate GA-67's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Gallium Citrate GA-67 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Gallium Citrate GA-67 suppliers with USDMF on PharmaCompass.
Gallium Citrate GA-67 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gallium Citrate GA-67 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gallium Citrate GA-67 GMP manufacturer or Gallium Citrate GA-67 GMP API supplier for your needs.
A Gallium Citrate GA-67 CoA (Certificate of Analysis) is a formal document that attests to Gallium Citrate GA-67's compliance with Gallium Citrate GA-67 specifications and serves as a tool for batch-level quality control.
Gallium Citrate GA-67 CoA mostly includes findings from lab analyses of a specific batch. For each Gallium Citrate GA-67 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gallium Citrate GA-67 may be tested according to a variety of international standards, such as European Pharmacopoeia (Gallium Citrate GA-67 EP), Gallium Citrate GA-67 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gallium Citrate GA-67 USP).
LOOKING FOR A SUPPLIER?